Article Data

  • Views 435
  • Dowloads 113

Original Research

Open Access

Immediate risk of HSIL presence in women who have both ASC-US cytology and negative high-risk HPV test

  • M. Ozturk1,*,
  • H. Umudum2
  • A. Aydin1
  • M. Ulubay3
  • U. Keskin3
  • M. Dede3
  • M.C. Yenen3

1Etimesgut Military Hospital Obstetrics and Gynecology Department, Etimesgut, Ankara, Turkey

2Etimesgut Military Hospital Pathology Department, Etimesgut, Ankara, Turkey

3Gulhane Military Medical Academy, Obstetrics and Gynecology Department, Etlik, Ankara, Turkey

DOI: 10.12892/ejgo2848.2016 Vol.37,Issue 2,April 2016 pp.232-237

Published: 10 April 2016

*Corresponding Author(s): M. Ozturk E-mail:


Purpose: The authors aimed to detect immediate risk of having high grade squamous lesions (HSIL) in atypical squamous cells of uncertain significance(AS-CUS) and concomitant high-risk human papillomavirus (HrHPV) testing as negative [HrHPV(negative)ASCUS]. Materials and Methods: The authors performed immediate/baseline colposcopy on concomitant HrHPV (negative)AS-CUS cases. Pap tests were evaluated with liquid-based cytology (LBC) and HrHPV detection was performed in LBC material with PCR. Colposcopic diagnoses and biopsy results were compared with Pap test and HrHPV test results. Results: There were 104 patients over a oneyear period. In all, 84 cases were included. Colposcopic biopsies revealed low grade squamous intraepithelial lesion (LSIL) in 19 cases (23%) and HSIL in three cases (4%). Intrauterine device use and smoking were significantly correlated with presence of HSIL (p = 0.005 and p = 0.007 respectively). Conclusion: Similar data in literature, 4% of ASC-US-HrHPV (negative) cases are expected to have HSIL in follow-up periods less than six months. The present authors believe clinicians should be more open with their patients about limitations of Pap-HPV testing.


ASC-US; Cervical cancer screening; Human papillomavirus; Human papillomavirus DNA tests.

Cite and Share

M. Ozturk,H. Umudum,A. Aydin,M. Ulubay,U. Keskin,M. Dede,M.C. Yenen. Immediate risk of HSIL presence in women who have both ASC-US cytology and negative high-risk HPV test. European Journal of Gynaecological Oncology. 2016. 37(2);232-237.


[1] Eversole G.M., Moriarty A.T., Schwartz M.R., Clayton A.C., Souers R., Fatheree L.A., et al.: “Practices of participants in the college of american pathologists interlaboratory comparison program in cervicovaginal cytology, 2006”. Arch. Pathol. Lab. Med., 2010, 134, 331.

[2] Turkish Cervical Cancer And Cervical Cytology Research Group: “Prevalence of cervical cytological abnormalities in Turkey”. Int. J. Gynaecol. Obstet., 2009, 106, 206.

[3] Cox J.T.: “Management of atypical squamous cells of undetermined significance and low-grade squamous intra-epithelial lesion by human papillomavirus testing”. Best Pract. Res. Clin. Obstet. Gynaecol., 2001, 15, 715.

[4] Massad L.S., Einstein M.H., Huh W.K., Katki H.A., Kinney W.K., Schiffman M., et al.: “2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors”. J. Low Genit. Tract. Dis., 2013, 17, S1.

[5] Stafl A., Wilbanks G.D.: “An international terminology of colposcopy: report of the Nomenclature Committee of the International Federation of Cervical Pathology and Colposcopy”. Obstet. Gynecol., 1991, 77, 313.

[6] The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: “Background and Consensus Recommendations From the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology”. J. Low. Genit. Tract Dis., 2012, 16, 205.

[7] Austin R.M.: “Human papillomavirus reporting: minimizing patient and laboratory risk”. Arch. Pathol. Lab. Med., 2003, 127, 973.

[8] Eltoum I.A., Chhieng D.C., Crowe D.R., Roberson J., Jin G., Broker T. R.: “Significance and possible causes of false-negative results of reflex human Papillomavirus infection testing”. Cancer, 2007, 111, 154.

[9] Lonky N.M., Felix J.C., Naidu Y.M., Wolde-Tsadik G.: “Triage of atypical squamous cells of undetermined significancewith Hybrid Capture II: colposcopy and histologic human papillomavirus correlation”. Obstet. Gynecol., 2003, 101, 481.

[10] Lonky N.M., Mahdavi A., Wolde-Tsadik G., Bajamundi K., Felix J.C.: “Evaluation of the clinical performance of high-risk human papillomavirus testing for primary screening: a retrospective review of the Southern California Permanente Medical Group experience”. J. Low. Genit. Tract Dis., 2010, 14, 200.

[11] Katki H.A., Kinney W.K., Fetterman B., Lorey T., Poitras N.E., Cheung L., et al.: “Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice”. Lancet Oncol., 2011, 12, 663.

[12] Dillner J., Rebolj M., Birembaut P., Petry K.U., Szarewski A., Munk C., et al.: “Joint European Cohort Study. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study”. BMJ, 2008, 337, a1754.

[13] Castle P.E., Cox J.T., Jeronimo J., Solomon D., Wheeler C.M., Gravitt

P. E., et al.: “An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS)”. Obstet. Gynecol., 2008, 111, 847.

[14] Katki H.A., Schiffman M., Castle P.E., Fetterman B., Poitras N.E., Lorey T., et al.: “Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results”. J. Low. Genit. Tract Dis., 2013, 17, S36.

[15] Safaeian M., Solomon D., Wacholder S., Schiffman M., Castle P.: “Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squmous cells of undetermined significance”. Obstet. Gynecol., 2007, 109, 1325.

[16] Zuna R.E., Wang S.S., Rosenthal D.L., Jeronimo J., Schiffman M., Solomon D, ALTS Group: “Determinants of human papillomavirusnegative, low-grade squamous intraepithelial lesions in the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions triage study (ALTS)”. Cancer, 2005, 105, 253.

[17] Solomon D., Schiffman M., Tarone R.: “Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial”. J. Natl. Cancer Inst., 2001, 93, 293.

[18] Arbyn M., Buntinx F., Van Ranst M., Paraskevaidis E., Martin-Hirsch P., Dillner J.: “Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia”. J. Natl. Cancer Inst., 2004, 96, 280.

[19] Guyot A., Fox J., Karim S., Kyi M.: “Possible causes of low sensitiv-ity of HPV-DNA testing for CIN2/3”. Acta Obstet. Gynecol. Scand., 2004, 83, 217.

[20] Pino M., Rodriguez-Carunchio L., Alonso I., Torné A., Rodriguez A., Fusté P., et al.: “Clinical, colposcopic and pathological characteristics of cervical and vaginal high-grade lesions negative for HPV by Hybrid Capture 2”. Gynecol. Oncol., 2011, 122, 515.

[21] Jastania R., Geddie W.R., Chapman W., Boerner S.: “Characteristics of apparently false-negative digene hybrid capture 2 high-risk HPV DNA testing”. Am. J. Clin. Pathol., 2006, 125, 223.

[22] Dalla Palma P., Giorgi Rossi P., Collina G., Buccoliero A.M., Ghiringhello B., Gilioli E., et al.: “The reproducibility of CIN diagnoses among different pathologists data from histology reviews from a multicenter randomized study”. Am. J. Clin. Pathol., 2009, 132, 125.

[23] Yetimalar H., Kasap B., Cukurova K., Yildiz A., Keklik A., Soylu F.: “Cofactors in human papillomavirus infection and cervical carcinogenesis”. Arch. Gynecol. Obstet., 2012, 285, 805.

[24] Santoso J.T., Crigger M., English E., Wan J., Likes W.: “Smoking cessation counseling in women with genital intraepithelial neoplasia”. Gynecol. Oncol., 2012, 125, 716.

[25] Castellsagué X., Díaz M., Vaccarella S., de Sanjosé S., Muñoz N., Herrero R., et al.: “Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies”. Lancet Oncol., 2011, 12, 1023.

[26] Committee on Practice Bulletins—Gynecology: “ACOG Practice Bul-letin Number 131: Screening for cervical cancer”. Obstet. Gynecol., 2012, 120, 1222.

[27] Zhao C., Li Z., Nayar R., Levi A.W., Winkler B.A., Moriarty A.T., et al.: “Prior high-risk human papillomavirus testing and papanicolaou test results of 70 invasive cervical carcinomas diagnosed in 2012: results of a retrospective multicenter study”. Arch. Pathol. Lab. Med., 2015, 139, 184. doi: 10.5858/arpa.2014-0028-OA. Epub 2014 Apr 2.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time